Compare PT & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PT | EDSA |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | China | Canada |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.7M | 12.8M |
| IPO Year | 2018 | N/A |
| Metric | PT | EDSA |
|---|---|---|
| Price | $0.94 | $1.29 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | ★ 60.0K | 34.5K |
| Earning Date | 09-19-2025 | 12-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,961,892.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 9.20 | N/A |
| 52 Week Low | $0.76 | $1.28 |
| 52 Week High | $1.38 | $4.49 |
| Indicator | PT | EDSA |
|---|---|---|
| Relative Strength Index (RSI) | 38.06 | 23.75 |
| Support Level | $0.93 | $1.43 |
| Resistance Level | $0.99 | $1.50 |
| Average True Range (ATR) | 0.05 | 0.08 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 6.41 | 4.59 |
Pintec Technology Holdings Ltd is a technology platform that provides financial services in China in terms of loan volume facilitated. The company connects business partners and financial partners on its open platform and enables them to provide financial services to end-users. Its products include installment loans, personal loans, wealth management, insurance brokerage, SME loans, and others. The company generates its revenue from technical service fees, as well as by providing financing for these borrowers and earning installment service fees. The company earns wealth management services fees and commissions on financial products. The company generates the majority of its revenue from Wealth management service fees and others.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.